

**TESTIMONY OF NAHELANI WEBSTER ON BEHALF OF  
GREENWICH BIOSCIENCES IN SUPPORT OF H.B. 542**

Date: February 25, 2021

Time: 2:00 p.m.

To: Chair Aaron Johanson and Members of the House Committee on Consumer Protection & Commerce.

My name is Nahelani Webster and I am presenting this testimony on behalf of Greenwich Biosciences in **support** of H.B. 542 Relating to the Uniform Controlled Substances Act.

Greenwich Biosciences, along with parent company GW Pharmaceuticals plc (“GW”), is the world leader in advancing the therapeutic potential of cannabinoids, naturally occurring compounds found in the cannabis plant. Leveraging over 20 years of pioneering research, the company is the first and only company to develop an FDA-approved, plant-derived prescription cannabinoid product, EPIDIOLEX (cannabidiol or CBD) oral solution. This means it has met the rigorous evaluation standards of the FDA for safety and efficacy.

The purpose of this bill is to update Hawaii state statute to make it consistent with amendments in the Federal Controlled Substances Act as required under Hawaii Revised Statutes (“HRS”) section 329-11. This bill will benefit patients who have been prescribed Epidiolex in Hawaii.

EPIDIOLEX was approved by the U.S. Food and Drug Administration (FDA) on June 25, 2018 for the treatment of seizures associated with Lennox Gastaux syndrome (LGS) and Dravet syndrome, two rare and difficult-to-treat forms of childhood-onset epilepsy, in patients two years of age or older.

In September 2018, the DEA placed Epidiolex in Schedule V of the Controlled Substances Act (CSA). Shortly after the DEA’s scheduling of Epidiolex, the Hawaii Department of Public Safety added Epidiolex to Schedule V of Hawaii’s Controlled Substances Act. HRS § 329-22(e); Haw. Dept. of Public Safety, Narcotics Enforcement Division, Notice of Federal Scheduling Action (Oct. 1, 2018).

On July 31, 2020, the FDA approved Epidiolex for a new indication – the treatment of seizures associated with Tuberous Sclerosis Complex, a rare genetic disease, in patients one year of age and older.

On March 20, 2020, Greenwich received correspondence from the DEA—confirming that, as a result of the federal 2018 Agricultural Improvement Act (“AIA”), Epidiolex has been descheduled under the CSA. As a consequence of the DEA’s letter, the FDA removed the Schedule V designation from the Epidiolex Prescribing Information Label.

On August 21, 2020, the DEA issued Interim Final Rule, removing Epidiolex from Schedule V under the CSA and making Epidiolex a descheduled drug.

EPIDIOLEX is prescribed for the treatment of seizures and is an additional medication for children and adults with Dravet, LGS, and Tuberous Sclerosis Complex, who were not previously helped with various epilepsy medicines. Greenwich is seeking solutions that will transform lives, and this is why Greenwich continues to advance cannabinoid science and study new medications to help meet serious unmet patient and caregiver needs.

Thank you for the opportunity to present this testimony. Please contact me if you have any questions.

**HB-542**

Submitted on: 2/24/2021 12:16:36 PM

Testimony for CPC on 2/25/2021 2:00:00 PM

<b>Submitted By</b>	<b>Organization</b>	<b>Testifier Position</b>	<b>Present at Hearing</b>
Duane Sosa	Individual	Support	No

Comments:

Aloha!!!

My name is Duane Sosa. I am humbly submitting testimony in SUPPORT of HB542. The decriminalization Cannibas should of happend a long time ago.

Mahalo